Branch Retinal Vein Occlusion
Conditions
Brief summary
The aim of this study is to evaluate the visual outcome and prognostic factors after intraocular injections of Bevacizumab or combination of Bevacizumab And Dexamethasone under pro re nata treatment regimen for Branch Retinal Vein Occlusion (BRVO) patients.
Detailed description
The aim of this study is to evaluate the clinical outcome after intraocular injections of Bevacizumab or combination of Bevacizumab and Dexamethasone under pro re nata treatment regimen for the patients with Branch Retinal Vein Occlusion (BRVO) patients. Mean change of logarithm of the minimal angle of resolution (logMAR) visual acuity (VA), central foveal thickness (CFT), contrast sensitivity (CS) as well as predictive factors including best-corrected visual acuity (BCVA), vision related questionnaires and various other ocular parameters will be assessed.
Interventions
DRUGBevacizumab Ophthalmic and Intravitreal Dexamethasone
Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
DRUGBevacizumab Ophthalmic
Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
Sponsors
He Eye Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Written informed consent must be obtained before any study assessment is performed 2. Diagnosis of visual impairment exclusively due to ME secondary to BRVO 3. BCVA score at Screening and Baseline between 10/40 (0.5) to 20/400 (0.05) on the Snellen chart. 4. Central foveal thickness (CFT) ≥ 300 µm 5. Naive Eyes
Exclusion criteria
1. Pregnant or nursing (lactating) women 2. Stroke or myocardial infarction less than 3 months before Screening 3. Uncontrolled blood pressure defined as systolic value of \>160 mm Hg or diastolic value of \>100 mm Hg at Screening or Baseline. 4. Any active periocular or ocular infection or inflammation at Screening or Baseline in either eye 5. Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before Baseline in either eye 6. Neovascularization of the iris or neovascular glaucoma in the study eye 7. Use of any systemic or ocular antivascular endothelial growth factor (anti-VEGF) drugs within 6 months before Baseline 8. Panretinal laser photocoagulation performed, anticipated or scheduled in the study eye 9. Focal or grid laser photocoagulation in the study eye 10. Use of intra- or periocular corticosteroids (including sub-Tenon) or ocular anti-VEGF treatment within 3 months before Screening in the study eye 11. Any use of intraocular corticosteroid implants (eg, dexamethasone \[Ozurdex®\], fluocinolone acetonide \[Iluvien®\]) in the study eye
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean change in monocular BCVA in the treatment eye | Baseline, 1 week, 1month, 2 months, 3 months, and 6 months. | Monocular BCVA in the treatment eye is assessed by using ETDRS visual acuity charts at 4 meters is assessed and compared. |
| Mean change in binocular BCVA | Baseline, 1 week, 1month, 2 months, 3 months, and 6 months. | Binocular BCVA is assessed by using ETDRS visual acuity charts at 4 meters is assessed and compared. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Bevacizumab. Treatments | Day 1 through Month 6 | Number of injections provided to the patients during the 6 month period. |
| Mean change in NEI VFQ25 | Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months. | Scores from NEI VFQ25 questionnaire is assessed and compared. |
| Mean change in EQ-5D 5L | Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months. | Scores from EQ-5D 5L questionnaire is assessed and compared. |
| Mean change in VisQoL scores | Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months. | Scores from VisQoL questionnaire is assessed and compared. |
| Mean change in central subfield retinal thickness | Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months. | Mean change in central subfield retinal thickness in the study eye, as determined by spectral domain optical coherence tomography (OCT) is assessed and compared. |
| Mean change in ocular surface and tear-film | Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months. | Mean deviation (MD) of ocular surface and tear-film parameters is assessed by Oculus Keratographer test and compared. |
| Mean change in vessel density | Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months. | Mean deviation (MD) of vessel density is assessed by Spectralis OCT2, Heidelberg-Engineering test and compared. |
| Side effects | Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months. | Side effects are measured by a review of the participant's medical and ophthalmic history. |
| People meeting driving standards | Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months. | Percentage (%) of people meeting driving standards is assessed by an Esterman binocular visual field test and compared. |
| Mean change in wavefront aberrations | Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months. | Mean deviation (MD) of wavefront aberrations is assessed by Nidek OPD Scan III and compared. |
| Change in Humphrey 10-2 visual field in the treatment eye | Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months. | Mean deviation (MD) of the Humphrey 10-2 visual field is assessed by a Humphrey 10-2 visual field test and compared. |
Countries
China
Contacts
Primary ContactJun Li, M.D., Ph.D.
Backup ContactEmmanuel E Pazo
Outcome results
None listed